|Bid||59.00 x 4000|
|Ask||0.00 x 3200|
|Day's Range||60.94 - 61.87|
|52 Week Range||43.10 - 64.60|
|PE Ratio (TTM)||229.41|
|Forward Dividend & Yield||1.12 (1.88%)|
|1y Target Est||N/A|
In 1Q18, Valeant Pharmaceuticals’ (VRX) subsidiary, Bausch + Lomb, generated revenues of $1.10 billion compared to $1.13 billion in 1Q17, which reflected an ~3.0% decline on a year-over-year (or YoY) basis. In 1Q18, Bausch + Lomb witnessed 2.0% organic growth compared to 1Q17.
Abbott Laboratories (NYSE:ABT) generated a below-average return on equity of 1.19% in the past 12 months, while its industry returned 10.98%. ABT’s results could indicate a relatively inefficient operation toRead More...
An increasingly common cardiovascular procedure using a device made by several medical technology companies was no better than drug therapy at preventing deaths, strokes and certain other complications, a new study found. The outcome of the trial raises questions about the procedure, known as catheter ablation, to treat patients with atrial fibrillation. Abbott Laboratories, Johnson & Johnson, Medtronic PLC and Boston Scientific Corp. make the device used in the procedure.
Merck’s (MRK) diabetes products include blockbuster drugs Januvia (sitagliptin) and Janumet (sitagliptin and metformin hydrochloride). Both drugs are used to control blood sugar levels in patients with diabetes.
Allergan (AGN) surpassed Wall Street analysts’ estimates for earnings per share (or EPS) and revenues, reporting EPS of $3.74 on revenues of $3.7 billion during 1Q18. Analysts expect Allergan’s top line to fall 3.3% to ~$3.9 billion in 2Q18. Its earnings per share are expected to reach $4.03 in 2Q18. The chart below shows analysts’ recommendations over the last 12 months.
On May 3, Abbott Laboratories (ABT) was trading at a forward PE (price-to-earnings) ratio of 19.2x, while its PE ratio was 55.7x. This compares to the company’s forward PE and LTM (last-12-months) PE multiples of 20.1x and 57.6x, respectively, in April.
Today we’re going to take a look at the well-established Abbott Laboratories (NYSE:ABT). The company’s stock received a lot of attention from a substantial price movement on the NYSE overRead More...
(Continued from Prior Part)Alere acquisition integration progress Abbott Laboratories (ABT) completed its acquisition of Alere in October 2017. The company has experienced significant difficulties with the acquisition over the past year. Let’s take a look at how the acquisition has progressed. According to Abbott Laboratories, the bulk of the integration work is complete, and the company has established strategies and plans for the Alere business. The company added that the Alere acquisition’s synergies are on track, and the company seems to have benefited from the deal. ...
Abbott Laboratories (ABT) has registered some pressure in its China Nutritionals business. Over the past year, the market has seen trends such as oversupply leading to price discounting due to new food safety regulations that should become effective in 2018. Since the new food safety regulations have come into effect starting January 1, China’s nutrition market has seen improving market conditions.
In 1Q18, Abbott Laboratories (ABT) reported sales of $535.0 million in its CRM (Cardiac Rhythm Management) business, which contributed ~19.5% to the company’s total sales of $2.7 billion in the quarter. The segment’s sales, however, registered flat YoY (year-over-year) growth on an organic basis. Abbott’s Cardiovascular segment—consisting of its Rhythm Management, Electrophysiology, Heart Failure, Structural Heart, and Vascular businesses—reported sales of $2.1 billion in 1Q18.
Abbott Ventures chief Evan Norton may have spent part of his youth on a farm, but there’s no manure in his manner when speaking of the medical device and diagnostics market landscape. The key, he says, is to avoid being blindsided by the transformational power of digital data. “We’ve been competing against Medtronic and J&J, so that has the risk of us being disintermediated by other players that come into the market,” Norton told attendees at MedCity Invest, a meeting focused on health care entrepreneurs.
Abbott Laboratories (ABT) received FDA approval for its breakthrough CGM (continuous glucose monitoring) device, Freestyle Libre, in September 2017. For further details, please read Abbott’s Breakthrough CGM Device Freestyle Libre Wins FDA Approval. The company received reimbursement approval for the device from the Centers for Medicare & Medicaid Services in January 2018.
(Continued from Prior Part)ABT’s Medical Device business In 1Q18, Abbott Laboratories (ABT) registered sales of $7.4 billion, representing YoY (year-over-year) growth of ~16.7%. The company’s Medical Device segment registered strong growth and contributed ~37.0% to the company’s total sales, the highest of all four of its segments. ABT’s Medical Device segment sales came in at ~$2.7 billion in 1Q18. On a reported basis, the segment’s sales growth was ~14.6% on a YoY basis. However, on an organic basis, the segment’s sales increased ~9.4%. ...
On April 18, Abbott Laboratories (ABT) released its 1Q18 earnings results. The company registered revenues of $7.4 billion, which represents YoY (year-over-year) growth of ~16.7%. These sales results exceeded analysts’ estimates.
On May 2, Abbott Laboratories (ABT) ended trading at a closing price of $58.14 per share. Currently, the stock is trading lower than its 50-day moving average of $59.91 and near its 200-day moving average of $58.22.
In 1Q18, Abbott Laboratories (ABT) registered organic sales growth of ~6.9%, which came in at the high end of the company’s guidance range of 6.0%–7.0%. The company’s Nutrition segment is also picking up momentum while its Pharmaceuticals business was weaker than expected. The company, however, is confident of the sustainable growth going forward, boosted by recent launches and approvals.
Abbott Laboratories (ABT) reported its 1Q18 results on April 18. Let’s look at Wall Street analysts’ recommendations for ABT stock after its earnings release. On May 2, a Reuters survey noted that 20 brokerage firms were tracking ABT. Of these firms, 16 analysts recommended a “buy” or “strong buy.” The rest of the firms gave a “hold” rating on the stock. None of the firms gave a “sell” recommendation for Abbott Laboratories.
GlaxoSmithKline beat Wall Street Analysts’ estimates for earnings per share (or EPS) and revenues for 1Q18. It reported EPS of 24.60 pence on revenues of 7.22 billion pounds, compared to analysts’ estimated EPS of 24.21 pence at revenues of 7.20 billion pounds.
Key stock index funds rose Thursday as the FANG stocks and other big-cap techs powered big gains in the tech-heavy PowerShares QQQ Trust.